Details of the Drug

General Information of Drug (ID: DMA6S1D)

Drug Name

Ropinirole

Synonyms

Ropinirol; Ropinirolum; Ropitor; ReQuip CR; ReQuip XL; SKF 101468; Adartrel (TN); Requip (TN); Ropark (TN); Ropinirol[INN-Spanish]; Ropinirole (INN); Ropinirole [INN:BAN]; Ropinirolum [INN-Latin]; Ropitor (TN); SK&F 101468; SK&F-101,468; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1], [2]

Therapeutic Class

Antiparkinson Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

260.37

Topological Polar Surface Area (xlogp)

2.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 3.1234 micromolh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 0.0109 micromol/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 56 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 89% [3]
Clearance: The clearance of drug is 47 L/h [5]
Elimination: The majority of the absorbed dose is cleared by the liver, and more than 88% of a radiolabeled dose was recovered in urine [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 hours [7]
Metabolism: The drug is metabolized via the liver [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.3168 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.6% [9]
Vd: The volume of distribution (Vd) of drug is 7.5 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 133 mg/mL [4]

Chemical Identifiers

Formula: C16H24N2O
IUPAC Name: 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
Canonical SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
InChI: InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
InChIKey: UHSKFQJFRQCDBE-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5095
ChEBI ID: CHEBI:8888
CAS Number: 91374-21-9
DrugBank ID: DB00268
TTD ID: D0R9EQ
INTEDE ID: DR1440
ACDINA ID: D00606

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Modulator	[10]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Modulator	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Parkinson disease

ICD Disease Classification

8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ropinirole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Memantine	DMD9WSC	Minor	Additive dopaminergic effects by the combination of Ropinirole and Memantine.	Alzheimer disease [8A20]	[49]
Promazine	DMZAL7W	Moderate	Antagonize the effect of Ropinirole when combined with Promazine.	Appearance/behaviour symptom [MB23]	[50]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Ropinirole caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[51]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Ropinirole caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[51]
Norfloxacin	DMIZ6W2	Moderate	Decreased metabolism of Ropinirole caused by Norfloxacin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[51]
Grepafloxacin	DMGLX0T	Moderate	Decreased metabolism of Ropinirole caused by Grepafloxacin mediated inhibition of CYP450 enzyme.	Bronchitis [CA20]	[51]
Niclosamide	DMJAGXQ	Moderate	Decreased metabolism of Ropinirole caused by Niclosamide mediated inhibition of CYP450 enzyme.	Cestodes infection [1F70-1F76]	[51]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Ropinirole and Olopatadine.	Conjunctiva disorder [9A60]	[52]
Ropivacaine	DMSPJG2	Minor	Increased plasma concentrations of Ropinirole and Ropivacaine due to competitive inhibition of the same metabolic pathway.	Corneal disease [9A76-9A78]	[53]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Ropinirole caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[51]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Ropinirole when combined with OPC-34712.	Depression [6A70-6A7Z]	[50]
Amoxapine	DMKITQE	Moderate	Antagonize the effect of Ropinirole when combined with Amoxapine.	Depression [6A70-6A7Z]	[50]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Ropinirole and Esketamine.	Depression [6A70-6A7Z]	[54]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Ropinirole and Brimonidine.	Glaucoma [9C61]	[55]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Ropinirole caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[51]
Teriflunomide	DMQ2FKJ	Moderate	Increased metabolism of Ropinirole caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[54]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Ropinirole caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[51]
Propiomazine	DMKY8V1	Moderate	Antagonize the effect of Ropinirole when combined with Propiomazine.	Insomnia [7A00-7A0Z]	[50]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Ropinirole when combined with ITI-007.	Insomnia [7A00-7A0Z]	[50]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Ropinirole caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[56]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Ropinirole caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[51]
Primaquine	DMWQ16I	Moderate	Decreased metabolism of Ropinirole caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[51]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Ropinirole caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[57]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Ropinirole and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[58]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Ropinirole and Lasmiditan.	Migraine [8A80]	[59]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Ropinirole caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[60]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Ropinirole and Flibanserin.	Mood disorder [6A60-6E23]	[61]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Ropinirole and Thalidomide.	Multiple myeloma [2A83]	[62]
Droperidol	DM0DXA8	Moderate	Antagonize the effect of Ropinirole when combined with Droperidol.	Nausea/vomiting [MD90]	[50]
Prochlorperazine	DM53SRA	Moderate	Antagonize the effect of Ropinirole when combined with Prochlorperazine.	Nausea/vomiting [MD90]	[50]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Ropinirole when combined with Metoclopramide.	Nausea/vomiting [MD90]	[50]
Thiethylperazine	DMU3IET	Moderate	Antagonize the effect of Ropinirole when combined with Thiethylperazine.	Nausea/vomiting [MD90]	[50]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Ropinirole and Apraclonidine.	Optic nerve disorder [9C40]	[55]
Rofecoxib	DM3P5DA	Moderate	Decreased metabolism of Ropinirole caused by Rofecoxib mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[51]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Ropinirole caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[54]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Ropinirole caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[63]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Ropinirole and Dextropropoxyphene.	Pain [MG30-MG3Z]	[64]
Thiabendazole	DM7YCK3	Moderate	Decreased metabolism of Ropinirole caused by Thiabendazole mediated inhibition of CYP450 enzyme.	Parasitic worm infestation [1F90]	[51]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Ropinirole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[65]
Levomepromazine	DMIKFEL	Moderate	Antagonize the effect of Ropinirole when combined with Levomepromazine.	Psychotic disorder [6A20-6A25]	[50]
Fluphenazine	DMIT8LX	Moderate	Antagonize the effect of Ropinirole when combined with Fluphenazine.	Psychotic disorder [6A20-6A25]	[50]
Triflupromazine	DMKFQJP	Moderate	Antagonize the effect of Ropinirole when combined with Triflupromazine.	Psychotic disorder [6A20-6A25]	[50]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Ropinirole and Quetiapine.	Schizophrenia [6A20]	[50]
Mesoridazine	DM2ZGAN	Moderate	Antagonize the effect of Ropinirole when combined with Mesoridazine.	Schizophrenia [6A20]	[50]
Thioridazine	DM35M8J	Moderate	Antagonize the effect of Ropinirole when combined with Thioridazine.	Schizophrenia [6A20]	[50]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Ropinirole when combined with Aripiprazole.	Schizophrenia [6A20]	[50]
Iloperidone	DM6AUFY	Moderate	Antagonize the effect of Ropinirole when combined with Iloperidone.	Schizophrenia [6A20]	[50]
Paliperidone	DM7NPJS	Moderate	Antagonize the effect of Ropinirole when combined with Paliperidone.	Schizophrenia [6A20]	[50]
Loxapine	DM8AI9U	Moderate	Antagonize the effect of Ropinirole when combined with Loxapine.	Schizophrenia [6A20]	[50]
Haloperidol	DM96SE0	Moderate	Antagonize the effect of Ropinirole when combined with Haloperidol.	Schizophrenia [6A20]	[50]
Perphenazine	DMA4MRX	Moderate	Antagonize the effect of Ropinirole when combined with Perphenazine.	Schizophrenia [6A20]	[50]
Molindone	DMAH70G	Moderate	Antagonize the effect of Ropinirole when combined with Molindone.	Schizophrenia [6A20]	[50]
Chlorpromazine	DMBGZI3	Moderate	Antagonize the effect of Ropinirole when combined with Chlorpromazine.	Schizophrenia [6A20]	[50]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Ropinirole and Thiothixene.	Schizophrenia [6A20]	[50]
Clozapine	DMFC71L	Moderate	Antagonize the effect of Ropinirole when combined with Clozapine.	Schizophrenia [6A20]	[50]
Trifluoperazine	DMKBYWI	Moderate	Additive CNS depression effects by the combination of Ropinirole and Trifluoperazine.	Schizophrenia [6A20]	[50]
Risperidone	DMN6DXL	Moderate	Antagonize the effect of Ropinirole when combined with Risperidone.	Schizophrenia [6A20]	[50]
Olanzapine	DMPFN6Y	Moderate	Antagonize the effect of Ropinirole when combined with Olanzapine.	Schizophrenia [6A20]	[50]
Amisulpride	DMSJVAM	Major	Antagonize the effect of Ropinirole when combined with Amisulpride.	Schizophrenia [6A20]	[54]
Asenapine	DMSQZE2	Moderate	Antagonize the effect of Ropinirole when combined with Asenapine.	Schizophrenia [6A20]	[50]
Pimozide	DMW83TP	Moderate	Antagonize the effect of Ropinirole when combined with Pimozide.	Schizophrenia [6A20]	[50]
Warfarin	DMJYCVW	Moderate	Increased plasma concentration of Ropinirole and Warfarin due to competitive binding of plasma proteins.	Supraventricular tachyarrhythmia [BC81]	[66]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Ropinirole and Tizanidine.	Tonus and reflex abnormality [MB47]	[67]
Nalidixic acid	DMRM0JV	Moderate	Decreased metabolism of Ropinirole caused by Nalidixic acid mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[51]
Enoxacin	DMYTE6L	Moderate	Decreased metabolism of Ropinirole caused by Enoxacin mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[51]
Methdilazine	DMAUHQX	Moderate	Antagonize the effect of Ropinirole when combined with Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[50]
Trimeprazine	DMEMV9D	Moderate	Antagonize the effect of Ropinirole when combined with Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[68]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Ropinirole and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[69]
Mexiletine	DMCTE9R	Moderate	Decreased metabolism of Ropinirole caused by Mexiletine mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[51]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Ropinirole caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[51]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Ropinirole caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[51]
-----------


⏷ Show the Full List of 71 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Caprylic acid	E00017	379	Emulsifying agent; Flavoring agent; Surfactant
Carminic acid	E00506	10255083	Colorant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glyceryl behenate	E00481	5362585	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 39 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ropinirole 12 mg tablet	12 mg	24 HR Extended Release Oral Tablet	Oral
Ropinirole 0.25 mg tablet	0.25 mg	Oral Tablet	Oral
Ropinirole 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Ropinirole 1 mg tablet	1 mg	Oral Tablet	Oral
Ropinirole 2 mg tablet	2 mg	Oral Tablet	Oral
Ropinirole 4 mg tablet	4 mg	Oral Tablet	Oral
Ropinirole 5 mg tablet	5 mg	Oral Tablet	Oral
Ropinirole 4 mg tablet	4 mg	24 HR Extended Release Oral Tablet	Oral
Ropinirole 6 mg tablet	6 mg	24 HR Extended Release Oral Tablet	Oral
Ropinirole 8 mg tablet	8 mg	24 HR Extended Release Oral Tablet	Oral
Ropinirole 3 mg tablet	3 mg	Oral Tablet	Oral
Ropinirole 2 mg tablet	2 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7295).
2	Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:33-6.
3	FDA Approved Drug Products: OZEMPIC (semaglutide) injection, for subcutaneous use
4	BDDCS applied to over 900 drugs
5	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6	Ahire D, Sinha S, Brock B, Iyer R, Mandlekar S, Subramanian M: Metabolite Identification, Reaction Phenotyping, and Retrospective Drug-Drug Interaction Predictions of 17-Deacetylnorgestimate, the Active Component of the Oral Contraceptive Norgestimate. Drug Metab Dispos. 2017 Jun;45(6):676-685. doi: 10.1124/dmd.116.073940. Epub 2017 Mar 10.
7	Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000 Oct;39(4):243-54. doi: 10.2165/00003088-200039040-00001.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11	In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos. 1997 Jul;25(7):840-4.
12	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
13	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
24	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
25	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
26	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
27	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
28	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
30	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
31	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
32	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
33	Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
34	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
35	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
36	Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
37	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
38	Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
39	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
40	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
41	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
42	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
43	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
44	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
45	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
46	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
47	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
48	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
49	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
50	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
51	Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
52	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
53	Product Information. Naropin (ropivacaine). Astra USA, Westborough, MA.
54	Cerner Multum, Inc. "Australian Product Information.".
55	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
56	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
57	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
58	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
59	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
60	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
61	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
62	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
63	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
64	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
65	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
66	Bair JD, Oppelt TF "Warfarin and ropinirole interaction." Ann Pharmacother 35 (2001): 1202-4. [PMID: 11675845]
67	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
68	Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
69	Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.